322 related articles for article (PubMed ID: 25794132)
1. Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma.
Gonsalves WI; Leung N; Rajkumar SV; Dispenzieri A; Lacy MQ; Hayman SR; Buadi FK; Dingli D; Kapoor P; Go RS; Lin Y; Russell SJ; Lust JA; Zeldenrust S; Kyle RA; Gertz MA; Kumar SK
Blood Cancer J; 2015 Mar; 5(3):e296. PubMed ID: 25794132
[TBL] [Abstract][Full Text] [Related]
2. Cyclophosphamide-containing regimen (TCD) is superior to melphalan-containing regimen (MPT) in elderly multiple myeloma patients with renal impairment.
Song MK; Chung JS; Shin HJ; Moon JH; Lee JJ; Yoon SS; Kim JS; Lee JO; Do YR; Lee HS; Park EK;
Ann Hematol; 2012 Jun; 91(6):889-96. PubMed ID: 22237937
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, safety, and efficacy of lenalidomide plus dexamethasone in patients with multiple myeloma and renal impairment.
Bridoux F; Chen N; Moreau S; Arnulf B; Moumas E; Abraham J; Desport E; Jaccard A; Fermand JP
Cancer Chemother Pharmacol; 2016 Jul; 78(1):173-82. PubMed ID: 27286995
[TBL] [Abstract][Full Text] [Related]
4. Lack of Renal Recovery Predicts Poor Survival in Patients of Multiple Myeloma With Renal Impairment.
Sharma R; Jain A; Jandial A; Lad D; Khadwal A; Prakash G; Nada R; Aggarwal R; Ramachandran R; Varma N; Malhotra P
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):626-634. PubMed ID: 35610119
[TBL] [Abstract][Full Text] [Related]
5. Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment.
Dimopoulos MA; Christoulas D; Roussou M; Kastritis E; Migkou M; Gavriatopoulou M; Matsouka C; Mparmparoussi D; Psimenou E; Grapsa I; Efstathiou E; Terpos E
Eur J Haematol; 2010 Jul; 85(1):1-5. PubMed ID: 20192988
[TBL] [Abstract][Full Text] [Related]
6. Prognostic risk factor evaluation in patients with relapsed or refractory multiple myeloma receiving lenalidomide treatment: analysis of renal function by eGFR and of additional comorbidities by comorbidity appraisal.
Kleber M; Ihorst G; Udi J; Koch B; Wäsch R; Engelhardt M
Clin Lymphoma Myeloma Leuk; 2012 Feb; 12(1):38-48. PubMed ID: 22054851
[TBL] [Abstract][Full Text] [Related]
7. Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents.
Dimopoulos MA; Delimpasi S; Katodritou E; Vassou A; Kyrtsonis MC; Repousis P; Kartasis Z; Parcharidou A; Michael M; Michalis E; Gika D; Symeonidis A; Pouli A; Konstantopoulos K; Terpos E; Kastritis E
Ann Oncol; 2014 Jan; 25(1):195-200. PubMed ID: 24356630
[TBL] [Abstract][Full Text] [Related]
8. Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens.
Eleftherakis-Papapiakovou E; Kastritis E; Roussou M; Gkotzamanidou M; Grapsa I; Psimenou E; Nikitas N; Terpos E; Dimopoulos MA
Leuk Lymphoma; 2011 Dec; 52(12):2299-303. PubMed ID: 22141916
[TBL] [Abstract][Full Text] [Related]
9. Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment.
Klein U; Neben K; Hielscher T; Heiss C; Ho AD; Goldschmidt H
Ann Hematol; 2011 Apr; 90(4):429-39. PubMed ID: 20857112
[TBL] [Abstract][Full Text] [Related]
10. Detection of renal impairment as one specific comorbidity factor in multiple myeloma: multicenter study in 198 consecutive patients.
Kleber M; Ihorst G; Deschler B; Jakob C; Liebisch P; Koch B; Sezer O; Engelhardt M
Eur J Haematol; 2009 Dec; 83(6):519-27. PubMed ID: 19614956
[TBL] [Abstract][Full Text] [Related]
11. Renal Impairment at Diagnosis in Myeloma: Patient Characteristics, Treatment, and Impact on Outcomes. Results From the Australia and New Zealand Myeloma and Related Diseases Registry.
Ho PJ; Moore EM; McQuilten ZK; Wellard C; Bergin K; Augustson B; Blacklock H; Harrison SJ; Horvath N; King T; Mollee P; Quach H; Reid C; Rosengarten B; Walker P; Wood EM; Spencer A
Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):e415-e424. PubMed ID: 31208889
[TBL] [Abstract][Full Text] [Related]
12. Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials.
Siegel DS; Weisel KC; Dimopoulos MA; Baz R; Richardson P; Delforge M; Song KW; San Miguel JF; Moreau P; Goldschmidt H; Cavo M; Jagannath S; Yu X; Hong K; Sternas L; Zaki M; Palumbo A
Leuk Lymphoma; 2016 Dec; 57(12):2833-2838. PubMed ID: 27267105
[TBL] [Abstract][Full Text] [Related]
13. Severe renal impairment as an adverse prognostic factor for survival in newly diagnosed multiple myeloma patients.
Chen X; Luo X; Zu Y; Issa HA; Li L; Ye H; Yang T; Hu J; Wei L
J Clin Lab Anal; 2020 Sep; 34(9):e23416. PubMed ID: 32710448
[TBL] [Abstract][Full Text] [Related]
14. The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma.
Dimopoulos MA; Roussou M; Gkotzamanidou M; Nikitas N; Psimenou E; Mparmparoussi D; Matsouka C; Spyropoulou-Vlachou M; Terpos E; Kastritis E
Leukemia; 2013 Feb; 27(2):423-9. PubMed ID: 22763386
[TBL] [Abstract][Full Text] [Related]
15. Lenalidomide is effective and safe for the treatment of patients with relapsed multiple myeloma and very severe renal impairment.
João C; Freitas J; Gomes F; Geraldes C; Coelho I; Neves M; Lúcio P; Esteves S; Esteves GV
Ann Hematol; 2016 May; 95(6):931-6. PubMed ID: 27068406
[TBL] [Abstract][Full Text] [Related]
16. Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors.
Dimopoulos MA; Roussou M; Gavriatopoulou M; Zagouri F; Migkou M; Matsouka C; Barbarousi D; Christoulas D; Primenou E; Grapsa I; Terpos E; Kastritis E
Clin Lymphoma Myeloma; 2009 Aug; 9(4):302-6. PubMed ID: 19717380
[TBL] [Abstract][Full Text] [Related]
17. Response and Dynamics of Renal Function in Transplantation-Eligible Multiple Myeloma Patients Treated with a Novel Agent: The CAREMM-2201 Study.
Kim Y; Park SS; Jeon YW; Yahng SA; Shin SH; Min CK;
Transplant Cell Ther; 2023 Jan; 29(1):55.e1-55.e9. PubMed ID: 36202336
[TBL] [Abstract][Full Text] [Related]
18. A Report of 134 Newly Diagnosed Multiple Myeloma Patients with Renal Impairment.
Liu A; Yang G; Geng C; Wang H; Li L; Li Y; Wu Y; Tian Y; Leng Y; Wang G; Gao W; Chen W
Acta Haematol; 2016; 135(3):140-5. PubMed ID: 26587903
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment.
Zannetti BA; Zamagni E; Santostefano M; De Sanctis LB; Tacchetti P; Mancini E; Pantani L; Brioli A; Rizzo R; Mancuso K; Rocchi S; Pezzi A; Borsi E; Terragna C; Marzocchi G; Santoro A; Cavo M
Am J Hematol; 2015 Jul; 90(7):647-52. PubMed ID: 25858483
[TBL] [Abstract][Full Text] [Related]
20. Melphalan 200 mg/m
Sweiss K; Patel S; Culos K; Oh A; Rondelli D; Patel P
Bone Marrow Transplant; 2016 Oct; 51(10):1337-1341. PubMed ID: 27183094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]